Accelr8 Technology Corp. (AXK) Announces Results of Two Studies and Receives Approval to Present a New Blood Study
Accelr8 Technology today announced the promising results of two studies that it presented at the 112th annual General Meeting of the American Society for Microbiology. The first study involved the use of Accelr8’s BACcel™ rapid automated diagnostic system with positive blood cultures to identify a significant, complex multi-drug resistance expression type know as “ESBL.” The study showed that the system was capable of maintaining 100% sensitivity and 94% specificity while decreasing time to result by 1-2 days over the best standard method used today. Identifying ESBL resistance has become an incredibly important endeavor, as ESBL resistance has spread across the…